AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$HUM

Humana Non-GAAP EPS of -$0.70 beats by $0.30, revenue of $41.16B beats by $270M (HUM:NYSE)

Humana reported Q3 Non-GAAP EPS of -$0.70, beating estimates by $0.30, and revenue of $41.16B, exceeding expectations by $270M. The insurance segment's GAAP benefit ratio was 93.7%, better than guidance. The company raised its full-year outlook. (Source: Humana press release)

Original reporting
seekingalpha.com
Published Nov 6, 2026, 11:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 11:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$HUM
Bullish
high confidence
Mentioned
$HUM
Relevance
9/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$HUMBullishHigh
01

Why it matters

The beat on both EPS and revenue is likely to lift the stock in the near term.

02

Market read

Large‑cap health insurer with earnings beat; relevant for healthcare sector traders.

03

What to watch

Guidance outlook and insurance benefit ratio remain near guidance, which may temper upside.

Relevance 9/10Novelty 9/10Timing: post‑release today

Background

Humana's Q3 earnings release provides fresh financial metrics for investors.

Company-level read

Ticker impact

$HUMBullishHigh confidence
Context

Humana reported Q3 Non‑GAAP EPS of -$0.70 beating expectations by $0.30 and revenue of $41.16B beating by $270M.

Expected impact

upward pressure as market prices in the earnings beat

Evidence & confidence

Both EPS and revenue exceeded forecasts for a large‑cap insurer, prompting buying interest.

Market effects

Sector

Health insurance sector may see modest rally on strong earnings.

Regional

U.S. market may see slight gain in healthcare indices.

Global

Limited to U.S. equities; no broader global effect.

Counterpoint

What could challenge this read

Negative EPS despite beat could prompt short sellers to target the stock.

Key entities

  • Company
    Humana Inc.

    U.S. health insurance provider.

Read at source← All news

StoryHumana posts Q3 2026 results and lifts FY2026 adjusted EPS guidance to at least $9.50

Also covered by

6 outlets

Related articles

$HUMHighAI 8/10

Humana Raises Profit Floor on Lower Costs

Humana (HUM) raised its 2026 adjusted earnings guidance to at least $9.50 per share from $9.00, citing lower costs. Q3 insurance benefit ratio was 93.7%, better than expected. Shares fell 0.59% in pre-market trading. Humana's Medicare Advantage membership grew 23% this year.

asktraders.com
$HUMHighAI 8/10

HUM Q3 FY2026 earnings call

Humana Inc. reported Q3 2026 earnings exceeding expectations, raising full-year adjusted EPS guidance to at least $9.50. The company cited favorable medical cost trends and strong execution. Management highlighted progress in clinical quality, Medicaid expansion, and capital allocation, including a divestiture and a new joint venture. Humana expects 2027 Medicare Advantage membership growth and an 8%-9% medical cost trend, with risks and opportunities outlined.

finance.biggo.com
$HUMHighAI 8/10

[Humana Q3 2026 Earnings Call] Humana Lifts Full-Year EPS Guidance to at Least $9.50 as Medical Cost Trend Lands at Low End of 7%-8% Range

Humana Inc. raised its full-year 2026 adjusted EPS guidance to at least $9.50 per share from $9.00, citing favorable medical cost trends. The company reported strong STARS performance and plans to use excess funds for investments and shareholder returns. Humana also announced balance sheet improvements through divestitures and a new joint venture with BlackRock. Management expects 2027 Medicare Advantage membership growth and higher medical cost trends.

finance.biggo.com
$HUMMed

Humana Lifted Its Profit Forecast As Medical Costs Cooled

Humana raised its profit forecast due to lower medical costs, despite posting an adjusted quarterly loss. The company reported a 93.7% medical cost ratio, which may influence its Medicare Advantage pricing. Humana's individual Medicare Advantage membership grew 23% year-to-date, with a target of 25% growth by 2026 and a pretax margin of at least 3% by 2028.

finimize.com